Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. - Wikidata - awgldk - TriplyDB

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

http://www.wikidata.org/entity/Q35751042

about

Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets The TOR pathway comes of age Potential use of rapamycin in HIV infection The mTOR signalling pathway in human cancer Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice Targeting the mTOR signaling network for cancer therapy Role of mTOR Inhibitors in Kidney Disease PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms Optimizing treatments for lymphangioleiomyomatosis Nutrient regulation of the mTOR complex 1 signaling pathway Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells.The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Enhancing mTOR-targeted cancer therapy.Epistemology of the origin of cancer: a new paradigm.Targeting the translational machinery as a novel treatment strategy for hematologic malignancies Immunoregulatory functions of mTOR inhibition.Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3β signaling Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases.Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells.Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.Extra-thymically induced regulatory T cells: do they have potential in disease prevention?Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model.The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going Change or die: targeting adaptive signaling to kinase inhibition in cancer cells.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells.mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease.Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.TSC1 controls distribution of actin fibers through its effect on function of Rho family of small GTPases and regulates cell migration and polarity.mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells.mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia.AP-1 regulates cyclin D1 and c-MYC transcription in an AKT-dependent manner in response to mTOR inhibition: role of AIP4/Itch-mediated JUNB degradation Branched chain amino acid suppresses hepatocellular cancer stem cells through the activation of mammalian target of rapamycin Molecular interplay between leptin, insulin-like growth factor-1, and β-amyloid in organotypic slices from rabbit hippocampus.

P2860

Q21136406-B69D0C67-70E1-4128-AD0B-1FF04716EC23 Q21183974-47FAE06B-DC64-404E-B6DE-7A8D55823F68 Q24568353-8B50DB50-2789-47CC-A1F6-95E2272506D9 Q24606795-7CCF6178-811C-462C-A2A6-47E908BB3F09 Q24627306-00B67410-0A00-421D-AD47-38068D9D32A1 Q24632296-AA8BEDAD-32E6-4102-9E48-AC41BEF71F7A Q24658113-1E339FDD-7F10-4614-B8A3-709AD8A0BAA4 Q24658334-6D9D06AE-3C3A-4FB0-9959-25EB36CFCFDE Q26747506-A23FEAF4-E70E-4950-9CBE-C5151AD89B87 Q26862544-B20E7DD8-B5EC-4463-9FE7-E644F2D7DEA9 Q26865250-348698FC-B43F-4540-AC8F-BAB5EDB29516 Q27027823-313D2F5D-39E1-44FE-841C-2C0F1B039E3A Q28076041-D0EAEA21-06E2-4596-91AC-B27AB53C9E1C Q31037798-8A9D4192-23AB-41A7-9B84-C828057CFB8A Q33437313-8804D57F-3467-45A4-B903-52E048EF57AA Q33493174-27B08F34-075C-4C7C-BE75-05A64D2F3069 Q33604979-56743458-8410-4C72-855E-D728A283E999 Q33631655-73DADE1B-0BF2-4490-BA6B-886E2776F282 Q33747291-306D4EFE-A28F-4EA8-821F-BC879796EDE9 Q33761278-F0B36A71-DAC5-4D77-BFC5-D965ABCE7E75 Q33798469-29B35D59-FD03-49B1-BEE6-F468B5515445 Q33799555-4554BE1A-3996-4A53-A4FE-62196DA50638 Q33875609-138937D0-A6A3-4C5B-97B3-90D59EC6A571 Q33947770-3BCE61FE-5C65-4EC4-8DE8-D3EAA952DA8C Q33949282-1F9E2494-2866-4069-8466-4D93D9B802D0 Q33952803-C7DDD093-58C8-46BE-9289-0575785302AC Q34012236-FD03BA52-9E78-4C39-BADB-1F3523087006 Q34024558-41D6D0F2-8AF1-4D21-AA73-F59A3083DAFF Q34167429-0CAB98B5-E373-436E-99AA-3C4453C2AD0C Q34225871-E5B0C187-BE60-4FCE-B806-79F931824B2E Q34260622-E23689FB-8F62-47FC-A815-5657E89D211B Q34360637-E817C707-AC14-4146-B0AB-C03DDF96B202 Q34501913-3271CF7D-5DF5-410B-BD40-44207B41A1AD Q34536450-2C64BD32-B1C3-45C1-B8EA-DAAE3738DDB1 Q34565046-4A7C60A0-689F-45F0-AB75-637AAA05C246 Q34675637-98E05CAD-5282-41A8-A60B-37024B7D18D3 Q35003274-CD6B6613-9BF7-41AE-8910-18F76EFD38D7 Q35018011-46ECEE72-F4EB-49DA-95BC-AB1BEB04EC0B Q35060898-1A8421EA-D0C4-403E-8015-38B9D91D94B0 Q35063700-AD581B39-8924-49E9-84A4-B64192FDAB02

P2860

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

http://www.wikidata.org/entity/Q35751042

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

@ast

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

@en

type

label

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

@ast

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

@en

prefLabel

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

@ast

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

@en

P1433

Q35751042-8A4FDA8C-DCA0-445F-BD37-4555CD51DF5A

P1476

Q35751042-BB3C8F5B-5515-4651-9571-7E44D3318158

P2093

Q35751042-1E70B13E-89BE-4713-8191-10A094ECA69C

Q35751042-2CCCB680-3C08-40E0-A4EA-02BA96E9E37D

Q35751042-3FE8099A-42A7-4036-BDB3-8B924D5B2355

Q35751042-5429CE2C-C3D6-43BB-94C1-6F180C5B040A

Q35751042-B7E68D65-C303-4B00-8A06-8909180675FE

Q35751042-CC0E3213-91C4-433E-9E67-EBC633F0CAC9

Q35751042-CE7D4A9C-4BC4-4A41-9314-52C9E82D999A

Q35751042-EE5DF586-92E8-4BAB-8A39-89E90C6EB11A

P2860

Q35751042-0A69E2FF-E54D-4A53-97E8-B5684FE57D15

Q35751042-2193D6CD-772D-4908-AAD7-0180CDE77DFD

Q35751042-3A49D62C-3A69-4525-96C0-29048DEB1D3D

Q35751042-4D3A259C-8B3F-496D-A300-A9C097CB2DDA

Q35751042-BB2C873A-D4DB-4A0C-8237-868F70591E65

Q35751042-BC4366BF-DB57-48DF-BCD0-64FCDD29704C

Q35751042-BF1106B7-0D55-482E-9058-04D87D0ABEB9

Q35751042-C5620978-9628-43B4-8F37-7E6890B12DB5

Q35751042-DE86E0C8-A60D-4921-8341-5FFB47F2C6F6

Q35751042-E1B6A55E-245B-4AD0-9E8F-F1066C8EE9EF

P304

Q35751042-CD4DF661-339D-4831-9EA7-96212827C43A

P31

Q35751042-9E00BBCE-B6D2-41E2-943D-53414F81AAD9

P356

Q35751042-0580E9F1-39B9-48AD-B0C6-5A2F6ED9061A

P407

Q35751042-84A83E07-62FE-4A3F-A508-70C8AF23A5F6

P433

Q35751042-F3B3F247-29E6-4220-8EBD-DC1048707FC4

P478

Q35751042-D17A2ADA-B31A-44BF-A3B9-6F9CA2698E00

P50

Q35751042-04B814D2-8CCE-4883-94B8-776C60B4E189

Q35751042-8ADD5378-8386-4AF9-BB6F-A2C0108A9228

P577

Q35751042-8B854248-5AE8-4012-AC18-1165ABFB9C0B

P5875

Q35751042-F90BEEC6-D319-4C30-9037-1345D4B06574

P698

Q35751042-70C58188-B4F1-4FDF-A016-0640589B6001

P932

Q35751042-9B5E15FF-D88D-4F82-9642-FDC747C6605A

P356

BLOOD-2006-06-030833

P1433

P1476

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

@en

P2093

C Ellen Jackson

http://www.w3.org/2001/XMLSchema#string

David M Sabatini

http://www.w3.org/2001/XMLSchema#string

Dos D Sarbassov

http://www.w3.org/2001/XMLSchema#string

Francis J Giles

http://www.w3.org/2001/XMLSchema#string

Ismael J Samudio

http://www.w3.org/2001/XMLSchema#string

Karen W L Yee

http://www.w3.org/2001/XMLSchema#string

Mark F Munsell

http://www.w3.org/2001/XMLSchema#string

Zhihong Zeng

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

TOR signaling in growth and metabolism

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

The TOR pathway: a target for cancer therapy

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.

Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies.

mTOR and cancer: reason for dancing at the crossroads?

A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR.

P304

3509-3512

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2006-06-030833

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Marina Konopleva

Michael Andreeff

P577

2006-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6621463

http://www.w3.org/2001/XMLSchema#string

P698

17179228

http://www.w3.org/2001/XMLSchema#string

P932

1852241

http://www.w3.org/2001/XMLSchema#string